secwatch.observer — SEC 8-K summary
======================================

Issuer:     Morphic Holding, Inc. (—)
CIK:        0001679363
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001679363-24-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Morphic Q1 net loss $45.3M ($0.91/sh); EMERALD-2 enrollment on track; CMO appointed
--------------------------------------------------------------------------------

- Net loss of $45.3M ($0.91/sh) vs. $36.1M ($0.90/sh) in Q1 2023; R&D expense $42.4M (up 39%).
- Cash, equivalents, and marketable securities $658.8M; cash runway into H2 2027.
- EMERALD-2 Phase 2b trial in UC enrollment on track; primary endpoint readout expected H1 2025.
- First patient dosing in GARNET Phase 2 Crohn's study expected Q2 2024.
- Appointed Dr. Simon Cooper as CMO; he previously developed risankizumab at AbbVie for UC and CD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1679363/000167936324000029/0001679363-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1679363/000167936324000029/morf-20240425.htm
  HTML page:      https://secwatch.observer/filing/0001679363-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer